Refine
Language
- English (170)
Has Fulltext
- yes (170)
Is part of the Bibliography
- no (170)
Keywords
- e +-e − Experiments (12)
- Branching fraction (8)
- BESIII (7)
- Particle and Resonance Production (7)
- Spectroscopy (5)
- Charm Physics (4)
- Quarkonium (4)
- Charmed mesons (3)
- Electroweak interaction (3)
- Exotics (3)
- Lepton colliders (3)
- e+-e− Experiments (3)
- Charm physics (2)
- Electroweak Interaction (2)
- Hadronic decays (2)
- Leptonic, semileptonic & radiative decays (2)
- Particle decays (2)
- QCD (2)
- BESIII detector (1)
- Bhabha (1)
- Born cross section measurement (1)
- Branching fractions (1)
- CP violation (1)
- Charmonium (1)
- Charmonium (-like) (1)
- Dark photon (1)
- Dark sector (1)
- Electromagnetic form factors (1)
- Experimental nuclear physics (1)
- Experimental particle physics (1)
- FOS: Physical sciences (1)
- Flavor changing neutral currents (1)
- Flavor symmetries (1)
- Flavour Physics (1)
- High Energy Physics - Experiment (hep-ex) (1)
- Initial state radiation (1)
- Invisible decays (1)
- Neutrinos (1)
- Particle and resonance production (1)
- Particle phenomena (1)
- Polarization (1)
- Proton (1)
- Radiative decay (1)
- Rare decays (1)
- Semi-leptonic decays (1)
- Y states (1)
- center-of-mass energy (1)
- charmonium-like states (1)
- dimuon (1)
- e+e − annihilation (1)
- e+e⁻ − Experiments (1)
- e+e− Experiments (1)
- electron-positron collision (1)
- hadron spectroscopy (1)
- hadronic events (1)
- helicity amplitude analysis (1)
- inclusive J/ψ decays (1)
- number of J/ψ events (1)
- tetraquark (1)
- trigger efficiency (1)
- Λ+c baryon (1)
Utilizing the data set corresponding to an integrated luminosity of 3.19 fb−1 collected by the BESIII detector at a center-of-mass energy of 4.178 GeV, we perform an amplitude analysis of the 𝐷+
𝑠→𝜋+𝜋−𝜋+ decay. The sample contains 13,797 candidates with a signal purity of ∼80%. The amplitude and phase of the contributing 𝜋𝜋 𝒮 wave are measured based on a quasi-model-independent approach, along with the amplitudes and phases of the 𝒫 and 𝒟 waves parametrized by Breit-Wigner models. The fit fractions of different intermediate decay channels are also reported.
Utilizing the data set corresponding to an integrated luminosity of 3.19 fb−1 collected by the BESIII detector at a center-of-mass energy of 4.178 GeV, we perform an amplitude analysis of the D+s→π+π−π+ decay. The sample contains 13,797 candidate events with a signal purity of ∼80%. We use a quasi-model-independent approach to measure the magnitude and phase of the D+s→π+π−π+ decay, where the P and D waves are parameterized by a sum of three Breit-Wigner amplitudes ρ(770)0, ρ(1450)0, and f2(1270). The fit fractions of different decay channels are also reported.
Utilizing the data set corresponding to an integrated luminosity of 3.19 fb−1 collected by the BESIII detector at a center-of-mass energy of 4.178 GeV, we perform an amplitude analysis of the D+s→π+π−π+ decay. The sample contains 13,797 candidates with a signal purity of ∼80%. The amplitude and phase of the contributing ππ S wave are measured based on a quasi-model-independent approach, along with the amplitudes and phases of the P and D waves parametrized by Breit-Wigner models. The fit fractions of different intermediate decay channels are also reported.
Using e+e− annihilation data corresponding to an integrated luminosity of 2.93 fb−1 taken at the center-of-mass energy s√=3.773~GeV with the BESIII detector, a joint amplitude analysis is performed on the decays D0→π+π−π+π− and D0→π+π−π0π0(non-η). The fit fractions of individual components are obtained, and large interferences among the dominant components of D0→a1(1260)π, D0→π(1300)π, D0→ρ(770)ρ(770) and D0→2(ππ)S are found in both channels. With the obtained amplitude model, the CP-even fractions of D0→π+π−π+π− and D0→π+π−π0π0(non-η) are determined to be (75.2±1.1stat.±1.5syst.)% and (68.9±1.5stat.±2.4syst.)%, respectively. The branching fractions of D0→π+π−π+π− and D0→π+π−π0π0(non-η) are measured to be (0.688±0.010stat.±0.010syst.)% and (0.951±0.025stat.±0.021syst.)%, respectively. The amplitude analysis provides an important model for binning strategy in the measurements of the strong phase parameters of D0→4π when used to determine the CKM angle γ(ϕ3) via the B−→DK− decay.
Using e+e− annihilation data corresponding to an integrated luminosity of 2.93 fb−1 taken at the center-of-mass energy s√=3.773~GeV with the BESIII detector, a joint amplitude analysis is performed on the decays D0→π+π−π+π− and D0→π+π−π0π0(non-η). The fit fractions of individual components are obtained, and large interferences among the dominant components of D0→a1(1260)π, D0→π(1300)π, D0→ρ(770)ρ(770) and D0→2(ππ)S are found in both channels. With the obtained amplitude model, the CP-even fractions of D0→π+π−π+π− and D0→π+π−π0π0(non-η) are determined to be (75.2±1.1stat.±1.5syst.)% and (68.9±1.5stat.±2.4syst.)%, respectively. The branching fractions of D0→π+π−π+π− and D0→π+π−π0π0(non-η) are measured to be (0.688±0.010stat.±0.010syst.)% and (0.951±0.025stat.±0.021syst.)%, respectively. The amplitude analysis provides an important model for binning strategy in the measurements of the strong phase parameters of D0→4π when used to determine the CKM angle γ(ϕ3) via the B−→DK− decay.
Using data samples with a total integrated luminosity of 20.1 fb−1 collected by the BESIII detector operating at the BEPCII collider, the cross section of the process 𝑒+𝑒−→𝜋+𝜋−𝜓(3686) is measured at center-of-mass energies between 4.0076 and 4.6984 GeV. The measured cross section is consistent with previous results, and with much improved precision. A fit to the measured energy-dependent cross section, which includes three Breit-Wigner functions and a nonresonant contribution, confirms the existence of the charmonium-like states 𝑌(4220), 𝑌(4390), and 𝑌(4660). This is the first observation of the 𝑌(4660) at the BESIII experiment.
The Born cross sections of the e+e− → D*+D*− and e+e− → D*+D− processes are measured using e+e− collision data collected with the BESIII experiment at center-of-mass energies from 4.085 to 4.600 GeV, corresponding to an integrated luminosity of 15.7 fb−1. The results are consistent with and more precise than the previous measurements by the Belle, Babar and CLEO collaborations. The measurements are essential for understanding the nature of vector charmonium and charmonium-like states.
Quantum-correlated 𝐷¯𝐷 pairs collected by the BESIII experiment at the 𝜓(3770) resonance corresponding to an integrated luminosity of 2.93 fb−1 are used to study the 𝐷0→𝐾0𝑆𝜋+𝜋−𝜋0 decay mode. The 𝐶𝑃-even fraction of 𝐷0→𝐾0𝑆𝜋+𝜋−𝜋0 decays is determined to be 0.235±0.010±0.002, where the first uncertainty is statistical and the second is systematic.
Importance Surgery is a mainstay in the management of hidradenitis suppurativa (HS). Adalimumab is the first drug approved for HS. Objective To investigate the efficacy and safety of adalimumab in combination with wide-excision surgery followed by secondary intention healing. Design, Setting, and Participants The Safety and Efficacy of Adalimumab for Hidradenitis Suppurativa Peri-Surgically (SHARPS) trial was a phase 4, randomized, double-blind, placebo-controlled study of adalimumab in conjunction with surgery. Patients were enrolled in 45 sites across 20 countries from July 18, 2016, to February 2, 2019, with the last patient visit on October 16, 2019. Eligible patients (aged 18-65 years) had moderate to severe HS that required radical surgery in an axillary or inguinal region and had 2 other anatomical regions affected, with 1 or more regions at Hurley stage II or III. Analysis was conducted in November 2019. Interventions Patients were randomized 1:1 to receive continuous adalimumab, 40 mg, or placebo during presurgery (12 weeks), perioperative (2 weeks), and postoperative (10 weeks) periods. Main Outcomes and Measures The primary end point was the proportion of patients achieving HS clinical response across all body regions at week 12. Results Overall, 103 patients were randomized to adalimumab and 103 to matching placebo. Among all patients, 51% (n = 106) were women, 94% (n = 193) were White, and the mean (SD) age was 37.6 (11.3) years. At week 12, significantly more patients receiving adalimumab (49 of 103 [48%]) vs placebo (35 of 103 [34%]; P = .049) achieved HS clinical response across all body regions (treatment difference, 14% [95% CI, 0%-27%]). Treatment-emergent adverse events were reported in 74 of 103 patients (72%) and 69 of 103 patients (67%) in the adalimumab and placebo groups, respectively. No increased risk of postoperative wound infection, complication, or hemorrhage was observed with adalimumab vs placebo. Two deaths occurred in the adalimumab group; neither was considered as having a reasonable possibility of relationship to study drug. Conclusions and Relevance Adalimumab was efficacious in conjunction with wide-excision surgery followed by secondary intention healing, with no need to interrupt treatment prior to surgery. These data support further investigation of adalimumab as an adjuvant therapy to surgery in patients with moderate to severe HS. Trial Registration ClinicalTrials.gov Identifier: NCT02808975